Takeuchi T, et al. - Efficacy and safety of sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 (IL-6) cytokine, was assessed in patients with active rheumatoid arthritis (RA) refractory to disease-modifying antirheumatic drugs in phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group SIRROUND-D study. With an expected safety profile, sirukumab afforded significant reductions in RA symptoms, inhibition of structural damage progression and physical function and quality of life improvements, when administered at a dose of 100 mg every 2 weeks and 50 mg every 4 weeks.